Date | Analyst | Company | Last | Target | Call | Valuation |
07/01/21 | CIMB | Ifast Corp | 8.15 | 8 | Add | |
07/26/21 | Lim & Tan | Ifast Corp | 9.18 | 0 | Take Profit | |
07/26/21 | UOB Kay Hian | Ifast Corp | 9.18 | 11.5 | Buy | DCF, PER73.1x FY22 |
07/27/21 | CIMB | Ifast Corp | 8.84 | 8.31 | Hold | |
07/27/21 | DBS Vickers | Ifast Corp | 8.84 | 12.1 | Buy | DCF |
08/02/21 | CIMB | Ifast Corp | 8.02 | 12.5 | Add | DCF |
10/21/21 | Citi Research | Ifast Corp | 9.88 | 7 | Sell | |
10/21/21 | UOB Kay Hian | Ifast Corp | 9.88 | 11.5 | Buy | DCF |
10/26/21 | Citi Research | Ifast Corp | 9.21 | 7.5 | Sell | |
10/26/21 | DBS Vickers | Ifast Corp | 9.21 | 12.93 | Buy | DCF |
01/10/22 | Citi Research | Ifast Corp | 7.85 | 7.5 | Sell | |
01/10/22 | DBS Vickers | Ifast Corp | 7.85 | 11.37 | Buy | DCF |
01/10/22 | UBS | Ifast Corp | 7.85 | 11 | Buy | |
01/13/22 | UOB Kay Hian | Ifast Corp | 7.86 | 9.75 | Buy | DCF |
01/27/22 | Citi Research | Ifast Corp | 6.84 | 6.2 | Sell | |
02/15/22 | Citi Research | Ifast Corp | 6.18 | 5.2 | Sell | |
02/15/22 | DBS Vickers | Ifast Corp | 6.18 | 10.85 | Buy | DCF |
02/17/22 | UOB Kay Hian | Ifast Corp | 6.36 | 9.84 | Buy | DCF |
04/25/22 | Citi Research | Ifast Corp | 5.66 | 5.2 | Sell | |
04/25/22 | DBS Vickers | Ifast Corp | 5.66 | 8.75 | Buy | DCF |
04/25/22 | UOB Kay Hian | Ifast Corp | 5.66 | 5.17 | Hold | PER40.3x FY22, Buy @ $4.40 |
04/26/22 | Citi Research | Ifast Corp | 5.31 | 4.2 | Sell | |
04/26/22 | DBS Vickers | Ifast Corp | 5.31 | 5.42 | Hold | DCF |
Monday, July 4, 2022
Ifast Corp - Stock calls
Hyphens Pharma - Stock calls
Date | Analyst | Company | Last | Target | Call | Valuation |
06/28/21 | Amfrasers | Hyphens Pharma | 0.315 | 0.43 | Buy | PER17x FY22 |
08/27/21 | SAC Capital | Hyphens Pharma | 0.31 | 0.37 | Buy | PER17.5x FY21 |
11/22/21 | Phillip | Hyphens Pharma | 0.3 | 0.345 | Accumulate | DCF |
01/07/22 | CIMB | Hyphens Pharma | 0.295 | 0.36 | Add | DCF, PER13.5x FY22 |
04/04/22 | Amfrasers | Hyphens Pharma | 0.29 | 0.38 | Outperform | PER15x FY22 |
04/07/22 | SAC Capital | Hyphens Pharma | 0.3 | 0.4 | Buy | |
05/13/22 | Lim & Tan | Hyphens Pharma | 0.28 | 0.37 | Buy | |
05/20/22 | CIMB | Hyphens Pharma | 0.28 | 0.36 | Add | |
05/20/22 | SAC Capital | Hyphens Pharma | 0.28 | 0.4 | Buy | |
06/06/22 | Phillip | Hyphens Pharma | 0.295 | 0.43 | Buy | DCF |
Stock calls for 4 July 2022
Date | Analyst | Company | Last | Target | Call | Valuation |
07/04/22 | Lim & Tan | Capitaland Investment | 3.79 | 4.27 | Buy | |
07/04/22 | DBS Vickers | ESR-Reit | 0.4 | 0.5 | Buy | DCF |
07/04/22 | DMG & Partners | Japan Foods | 0.425 | 0.55 | Buy | Sum of parts |
07/04/22 | Lim & Tan | Sembcorp Marine | 0.107 | 0.098 | Hold | |
07/04/22 | UOB Kay Hian | SIA Engineering | 2.42 | 2.8 | Buy | DCF |
Sunday, July 3, 2022
Financial risks are rising in the US! - Part 2
Part 1: https://sg-stock.blogspot.com/2022/07/financial-risks-are-rising-in-us.html
The Move Index has increased again and breached a 5-year peak.
The June ISM PMI declined to a 1-year low (53).
Just as we had expected, the June ISM PMI had declined. We had told our viewers to ignore the May ISM PMI previously because it was an aberration.
http://sg-stock.blogspot.com/2022/06/ism-pmi-increased-slightly-in-may-2022.html
Let's do an analysis of the June PMI to determine its outlook.
The prices subindex had eased to 78.5 (-3.7) because of an easing in supply disruption and a collapse in consumer demand. The new order (49.2, -5.9) had just entered a contractionary phase (below 50). Moreover, the new export order (50.7, -2.2) and new local order (Est’d -3.7) declined simultaneously. This had resulted in the backlog order decreasing to 53.2 (-5.5) as there were fewer unfulfilled orders. The customers’ inventories (35.2, +2.5) increased because of lower consumer spending.
The production had increased to 54.9 (+0.7) with lower employment (47.3, -2.3) and faster supplier’s deliveries (57.3, - 8.4) because of higher productivity. Employment was lower because of the bleak production outlook and difficulties in hiring. Thus, the inventories stayed relatively stable (56, +0.1).
In conclusion, the above factors caused the PMI to decline to a 1 year low of 53 (-3.1) and would continue its downward trajectory.
Saturday, July 2, 2022
Financial risks are rising in the US!
The risk index (Move) for the US bond market is going to breach a 5-year record high. This doesn't bode well for the bond market since a high move index denotes a bond bubble and high risk.
The high yield (Junk debt) spread is also rising which means investors are demanding higher risk premiums to buy debts. This doesn't bode well for the corporate debt market because companies will face more difficulties raising funds.
Main street sentiment in the US.
Let's take a look at the main street sentiment in the US to feel the economic pulse.